FDA approves treatments for irritable bowel syndrome
On May 27, the U.S. Food and Drug Administration (FDA) approved Viberzi (eluxadoline) and Xifaxan (rifaximin) for irritable bowel syndrome…
Common, complex, and chronic, IBS can markedly decrease the quality of life and work productivity. But by using an integrated approach, you can help patients manage their symptoms.
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.